Dr. Vikas Singh is a highly respected Consultant Urological Oncologist in Indore, offering specialized expertise in the comprehensive evaluation and advanced surgical treatment of Bladder Cancer (Urothelial Carcinoma). Fellowship-trained in state-of-the-art minimally invasive approaches, including sophisticated Transurethral Resection (TURBT) for early-stage disease and Robotic Radical Cystectomy for muscle-invasive disease, he is recognized as one of Indore’s leading bladder cancer surgeons, known for exceptional outcomes in managing complex urological malignancies. His treatment philosophy emphasizes precise initial staging through high-quality TURBT, which is fundamental for directing subsequent therapy. For advanced cases, his expertise encompasses performing complete cancer eradication and intricate urinary reconstruction, prioritizing patient quality of life. We maintain transparent discussions about treatment expenses and provide seamless insurance coordination for our patients throughout Central India.
Consultant Surgeon at Kokilaben Dhirubhai Ambani Hospital, Indore, employing cutting-edge Robotic technology.
Focused exclusively on Urological Oncology (Bladder, Prostate, Kidney, Testicular Cancers).
Advanced training in constructing neobladders and conduits following bladder removal.
The definitive method for initial diagnosis. A slender scope (Cystoscopy) is inserted through the urethra into the bladder to visualize tumors. When a growth is detected, a biopsy is obtained, and frequently the tumor is removed immediately through a Transurethral Resection of Bladder Tumor (TURBT) for precise staging.
CT Urography is a high-definition scan utilized to examine the complete urinary system (kidneys, ureters, bladder) for tumor extension and to exclude cancer in the upper tract. It confirms whether cancer is limited to the bladder or has metastasized, determining whether definitive surgery (Cystectomy) is necessary.
The pathology results from the initial TURBT are crucial. They establish whether the tumor is Non-Muscle-Invasive (NMIBC) or Muscle-Invasive (MIBC). This classification determines the treatment approach: either monitoring/intravesical therapy (for NMIBC) or radical surgery/chemoradiation (for MIBC).
This represents the primary treatment for Non-Muscle-Invasive Bladder Cancer (NMIBC). Performed endoscopically, the procedure involves inserting an instrument through the urethra to excise the tumor and cauterize the base. Dr. Singh employs sophisticated techniques like En Bloc Resection (removing the tumor as a single specimen) to ensure thorough removal, accurate staging, and to enhance response to subsequent treatments like BCG immunotherapy. Primary Goal: Complete tumor elimination for early-stage disease, highly precise staging, and bladder preservation.
For Muscle-Invasive Bladder Cancer (MIBC), radical surgery is essential. This entails complete removal of the bladder, adjacent lymph nodes, and potentially reproductive organs (Radical Cystectomy). Dr. Singh performs this intricate procedure utilizing the Da Vinci Robotic System, followed by careful urinary reconstruction (creating an Orthotopic Neobladder or Ileal Conduit). The robotic methodology minimizes blood loss, reduces incision size, and promotes faster recovery from this major, life-saving surgery. Primary Goal: Complete oncologic control, minimal surgical trauma, and careful reconstruction to maximize post-operative quality of life.
Bladder preservation is achievable for NMIBC through meticulous TURBT and subsequent therapy.
Minimally invasive technique means brief hospitalization (1-2 days) and swift return to work.
Robotic Cystectomy substantially reduces intra-operative bleeding risk versus open surgery.
A robotic platform facilitates the technically challenging creation of a neobladder or a continent diversion.
Schedule a private, confidential consultation with Dr. Singh in Indore.
The most common and significant initial symptom is painless blood in the urine (Hematuria). This blood may be visible (gross hematuria) or only detectable microscopically (microscopic hematuria). Since it’s often painless and intermittent, it’s frequently dismissed. Any occurrence of blood in urine must be investigated immediately with Cystoscopy.
While hematuria is the principal indicator, other symptoms can include increased urinary frequency, urgency, or painful urination (dysuria). These symptoms frequently resemble a urinary tract infection (UTI). If a patient receives UTI treatment but symptoms persist or rapidly return, a bladder cancer evaluation should be initiated.
Cystoscopy is the initial diagnostic procedure where a small camera examines the bladder interior. If a tumor is discovered, a Transurethral Resection of Bladder Tumor (TURBT) is performed. TURBT is essential; it removes the tumor and provides tissue for pathological examination to determine cancer stage and grade, which guides all subsequent treatment decisions.
NMIBC is cancer limited to the bladder’s innermost lining (mucosa or submucosa). Treatment typically involves TURBT followed by bladder instillation therapy (BCG). MIBC occurs when the tumor has invaded the thick muscular wall. This represents a life-threatening stage, and primary treatment usually requires Radical Cystectomy (bladder removal), often preceded by chemotherapy.
BCG (Bacillus Calmette-Guérin) is a live, attenuated bacterial vaccine introduced directly into the bladder through a catheter. It functions by triggering a localized immune response, stimulating the body’s immune cells to attack cancer cells in the bladder lining. It’s the standard treatment for high-risk NMIBC to prevent recurrence and progression following TURBT.
Radical Cystectomy is the surgical removal of the entire bladder, surrounding lymph nodes, and potentially reproductive organs. Performing this using the Da Vinci Robotic System (Robotic Radical Cystectomy) represents the preferred minimally invasive approach. Benefits include smaller incisions, reduced blood loss, decreased pain, and faster overall recovery compared to traditional open surgery.
The two primary options for creating a new urinary pathway (Urinary Diversion) are: 1. Orthotopic Neobladder (constructing a new internal bladder from an intestinal segment, enabling urination through the urethra) and 2. Ileal Conduit (a stoma/opening on the abdomen where urine drains into an external collection bag). The choice depends on patient health, dexterity, and quality-of-life objectives.
Yes. For Muscle-Invasive Bladder Cancer (MIBC), chemotherapy is frequently administered before radical cystectomy (termed neoadjuvant chemotherapy). This helps shrink the tumor, treat any microscopic spread, and significantly improves long-term survival outcomes. Chemotherapy may also be employed for metastatic (Stage 4) disease.
Follow-up is essential due to high recurrence risk. After TURBT for NMIBC, cystoscopies are typically performed every 3 months for the initial two years, then less frequently if the bladder remains disease-free. Following Radical Cystectomy, follow-up emphasizes monitoring the reconstructed urinary tract and detecting systemic recurrence through imaging scans (CT scans).
Hospital stay for Robotic Cystectomy is typically 7 to 10 days. Patients are encouraged to mobilize the day following surgery. While returning to light desk work may be possible in 2-3 weeks, complete physical recovery, including resuming heavy lifting or strenuous exercise, generally requires approximately 6 to 8 weeks. Comprehensive post-operative care and support are provided throughout recovery.
The leading center for advanced, compassionate urological care and treatment in Indore, Madhya Pradesh.
